SL T10
Alternative Names: SL-T10Latest Information Update: 03 May 2024
Price :
$50 *
At a glance
- Originator SL VAXiGEN
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 08 Apr 2024 SL VAXiGEN plans to launch SL T10 in 2026 (SL VAXiGEN pipeline, April 2024)
- 08 Apr 2024 SL VAXiGEN plans to initiate a global phase II trial for Prostate cancer (Hormone refractory) in 2025 (SL VAXiGEN pipeline, April 2024)